LINKS
CONTACT & CONNECT

Headquarters:

19950 W Country Club Drive
7th Floor

Aventura, FL 33180

International Offices:

Germany

info@ipdanalytics.com

+1 (305) 662-8515

  • LinkedIn Social Icon
  • Twitter Social Icon
Asset 211.png

© 2019 by IPD Analytics | Privacy Policy

Topics included in this episode:

  • HIV:

    • Integrase Strand Transfer Inhibitors (INSTIs) 

    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 

    • Non-Nucleoside Reverse Transcriptase Inhibitors
      (NNRTIs) 

    • Protease Inhibitors 

    • Two and Three Tablet Regimens 

    • Single Tablet Regimens 

    • New Guidelines for Recommended Regimens
      for First-line ART 

    • HIV Pipeline Drugs 

    • 505(b)(2)s 

    • Current Successful Management Strategies

    • Truvada and Descovy for PrEP 

  • Hepatitis C:
    • Recent Key Events 

    • Management Strategies 

"With the approval and launch of Descovy for HIV PrEP and the race for Gilead begins to move patients to this new therapy before generic Truvada launches in 2020, HIV is a hot topic for payers and providers alike. On the other end of the spectrum, we have Hep C, where curative therapies are available and management of this disease has become easier, but here at IPD we still receive questions surrounding Hep C and best practices. So seeing that these two topics are on top of mind, we figured let's have a discussion about both in terms of available therapies, what's coming down the clinical pipeline, and what actions payers can take to effectively manage their formularies."

Covering brands with upcoming loss of exclusivity, formulary management strategy, clinical pipeline, and generic pricing strategy, our Executive Clinical Pharmacy Team discusses HIV and Hepatitis C. 

IPD'S DRUG & CLINICAL REVIEW:

INFECTIOUS DISEASES: HIV AND HEPATITIS C
MANAGEMENT STRATEGY